Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.
作者信息
Connolly Caoilfhionn M, Frey Sarah, Chiang Teresa Po-Yu, Teles Mayan, Alejo Jennifer L, Albayda Jemima, Shah Ami A, Werbel William A, Segev Dorry L, Christopher-Stine Lisa, Paik Julie J
机构信息
Division of Rheumatology, Department of Medicine.
Department of Surgery.
出版信息
Rheumatology (Oxford). 2022 Oct 6;61(10):e302-e304. doi: 10.1093/rheumatology/keac298.
Abstract
摘要
相似文献
1
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.风湿性和肌肉骨骼疾病患者接种第三剂严重急性呼吸综合征冠状病毒2疫苗的安全性。
Rheumatology (Oxford). 2022 Oct 6;61(10):e302-e304. doi: 10.1093/rheumatology/keac298.
2
Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado .关于马查多所著的《风湿性和肌肉骨骼疾病患者接种新型冠状病毒疫苗的安全性：欧洲抗风湿病联盟冠状病毒疫苗（COVAX）医生报告登记处的结果》的通信
Ann Rheum Dis. 2023 Dec;82(12):e228. doi: 10.1136/annrheumdis-2022-222118. Epub 2022 Jul 11.
3
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.mRNA新型冠状病毒2疫苗首剂在风湿性和肌肉骨骼疾病患者中的安全性。
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
4
Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study.在风湿免疫疾病患者中，COVID-19 相关肺炎患者中使用灭活 SARS-CoV-2 疫苗的有效性和安全性：一项真实世界回顾性观察研究。
Int J Rheum Dis. 2024 May;27(5):e15166. doi: 10.1111/1756-185X.15166.
5
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.接种 SARS-CoV-2 疫苗在风湿免疫疾病患者中的安全性：来自 EULAR 冠状病毒疫苗（COVAX）医生报告登记处的结果。
Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.
6
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
7
Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗的安全性以及免疫抑制药物对风湿性疾病患者不良反应的影响。
Eur J Intern Med. 2023 Sep;115:137-139. doi: 10.1016/j.ejim.2023.06.014. Epub 2023 Jun 16.
8
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.风湿与肌肉骨骼疾病患者感染 SARS-CoV-2 及接种 SARS-CoV-2 疫苗的风险和预后：一项系统文献综述，旨在为 EULAR 建议提供信息。
Ann Rheum Dis. 2022 Mar;81(3):422-432. doi: 10.1136/annrheumdis-2021-221575. Epub 2021 Dec 7.
9
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.风湿性肌肉骨骼疾病患者接受 SARS-CoV-2 mRNA 疫苗后疾病发作频率较低。
Arthritis Res Ther. 2022 Jan 11;24(1):21. doi: 10.1186/s13075-021-02674-w.
10
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.欧洲抗风湿病联盟关于2019冠状病毒病背景下风湿性和肌肉骨骼疾病患者管理及疫苗接种的建议：2021年11月更新版
Ann Rheum Dis. 2022 Dec;81(12):1628-1639. doi: 10.1136/annrheumdis-2021-222006. Epub 2022 Feb 23.
引用本文的文献
1
Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines.提高血清转化不足的自身免疫性风湿病患者的疫苗反应：基于载体和灭活疫苗免疫原性分析
Cureus. 2024 Mar 7;16(3):e55764. doi: 10.7759/cureus.55764. eCollection 2024 Mar.
2
Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis.接种 COVID-19 疫苗是否与自身免疫性风湿病发作有关？一项自身对照病例系列分析。
Rheumatology (Oxford). 2023 Apr 3;62(4):1445-1450. doi: 10.1093/rheumatology/keac484.
本文引用的文献
1
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.第三次接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）mRNA疫苗后对奥密克戎反应性B细胞记忆的有效回忆
Cell. 2022 May 26;185(11):1875-1887.e8. doi: 10.1016/j.cell.2022.04.009. Epub 2022 Apr 8.
2
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.BNT162b2 mRNA新冠疫苗在接受免疫调节药物治疗的青少年风湿性疾病患者中的安全性和免疫原性。
Rheumatology (Oxford). 2022 Nov 2;61(11):4263-4272. doi: 10.1093/rheumatology/keac103.
3
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
4
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.风湿性肌肉骨骼疾病患者接受 SARS-CoV-2 mRNA 疫苗后疾病发作频率较低。
Arthritis Res Ther. 2022 Jan 11;24(1):21. doi: 10.1186/s13075-021-02674-w.
5
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.接种 SARS-CoV-2 疫苗在风湿免疫疾病患者中的安全性：来自 EULAR 冠状病毒疫苗（COVAX）医生报告登记处的结果。
Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.
6
A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients.第三剂 SARS-CoV-2 疫苗可提高实体器官移植受者对关注变异株的中和抗体。
Am J Transplant. 2022 Apr;22(4):1253-1260. doi: 10.1111/ajt.16933. Epub 2022 Jan 18.
7
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.成人系统性风湿病患者 COVID-19 疫苗接种的早期经验：来自 COVID-19 全球风湿病联盟疫苗调查的结果。
RMD Open. 2021 Sep;7(3). doi: 10.1136/rmdopen-2021-001814.
8
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.风湿和肌肉骨骼疾病患者在接受两剂 SARS-CoV-2 信使 RNA 疫苗接种后的疾病发作和反应原性。
Arthritis Rheumatol. 2022 Jan;74(1):28-32. doi: 10.1002/art.41924. Epub 2021 Dec 3.
Zotero 插件